Publications
RZ358
|
Single Dose Studies of RZ358 in Patients with Congenital Hyperinsulinism: Results of Population PK/PD Modeling and Simulation in Adult and Pediatric Patients
|
|
|
|
Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers
The Journal of Clinical Endocrinology & Metabolism, August 2017, 102(8):3021–3028 |
|
Activity of Xoma 358, an Inhibitor of Insulin Action Following Short-Term Administration to Congenital Hyperinsulinism Patients
ENDO 2017 Annual Meeting |
|
XOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial
ENDO 2015 Annual Meeting |
|
Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: A potential new approach for the treatment of hyperinsulinemic hypoglycemia
mAbs 6:1, 262–272; January/February 2014; © 2014 Landes Bioscience |
AB101
|
The Extended Duration Single Dose Pharmacokinetics (PK) and Pharmacodynamics (PD) of AB101, a Potential Once Weekly Basal Subcutaneous (SC) Insulin, in Diabetic Miniature Swine
2016 American Diabetes Association Scientific Sessions |
|
The in Vitro and in Vivo Pharmacology of AB101, a Potential Once-Weekly Basal Subcutaneous Insulin
2015 American Diabetes Association Scientific Sessions |
PKI Portfolio: RZ402
|
Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats
Diabetes, 60:1590–1598, May 2011 |
|
Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor–Stimulated Retinal Vascular Permeability
Hypertension, February 2009; 53:175-181 |